These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
243 related articles for article (PubMed ID: 17391433)
21. Optimal and consistent protein glycosylation in mammalian cell culture. Hossler P; Khattak SF; Li ZJ Glycobiology; 2009 Sep; 19(9):936-49. PubMed ID: 19494347 [TBL] [Abstract][Full Text] [Related]
22. N-Glycosylation of the human kappa opioid receptor enhances its stability but slows its trafficking along the biosynthesis pathway. Li JG; Chen C; Liu-Chen LY Biochemistry; 2007 Sep; 46(38):10960-70. PubMed ID: 17711303 [TBL] [Abstract][Full Text] [Related]
23. Expression of GnTIII in a recombinant anti-CD20 CHO production cell line: Expression of antibodies with altered glycoforms leads to an increase in ADCC through higher affinity for FC gamma RIII. Davies J; Jiang L; Pan LZ; LaBarre MJ; Anderson D; Reff M Biotechnol Bioeng; 2001 Aug; 74(4):288-94. PubMed ID: 11410853 [TBL] [Abstract][Full Text] [Related]
24. A dynamic mathematical model for monoclonal antibody N-linked glycosylation and nucleotide sugar donor transport within a maturing Golgi apparatus. Jimenez del Val I; Nagy JM; Kontoravdi C Biotechnol Prog; 2011; 27(6):1730-43. PubMed ID: 21956887 [TBL] [Abstract][Full Text] [Related]
25. How does mild hypothermia affect monoclonal antibody glycosylation? Sou SN; Sellick C; Lee K; Mason A; Kyriakopoulos S; Polizzi KM; Kontoravdi C Biotechnol Bioeng; 2015 Jun; 112(6):1165-76. PubMed ID: 25545631 [TBL] [Abstract][Full Text] [Related]
26. The way forward, enhanced characterization of therapeutic antibody glycosylation: comparison of three level mass spectrometry-based strategies. Wagner-Rousset E; Bednarczyk A; Bussat MC; Colas O; Corvaïa N; Schaeffer C; Van Dorsselaer A; Beck A J Chromatogr B Analyt Technol Biomed Life Sci; 2008 Sep; 872(1-2):23-37. PubMed ID: 18672411 [TBL] [Abstract][Full Text] [Related]
28. Importance of neonatal FcR in regulating the serum half-life of therapeutic proteins containing the Fc domain of human IgG1: a comparative study of the affinity of monoclonal antibodies and Fc-fusion proteins to human neonatal FcR. Suzuki T; Ishii-Watabe A; Tada M; Kobayashi T; Kanayasu-Toyoda T; Kawanishi T; Yamaguchi T J Immunol; 2010 Feb; 184(4):1968-76. PubMed ID: 20083659 [TBL] [Abstract][Full Text] [Related]
30. An integrated modular framework for modeling the effect of ammonium on the sialylation process of monoclonal antibodies produced by CHO cells. Savizi ISP; Motamedian E; E Lewis N; Jimenez Del Val I; Shojaosadati SA Biotechnol J; 2021 Aug; 16(8):e2100019. PubMed ID: 34021707 [TBL] [Abstract][Full Text] [Related]
31. O-linked glucosylation of a therapeutic recombinant humanised monoclonal antibody produced in CHO cells. Tanaka M; Koga A; Kobe A; Sekimori Y; Aso Y; Terada K Eur J Pharm Biopharm; 2013 Feb; 83(2):123-30. PubMed ID: 23183444 [TBL] [Abstract][Full Text] [Related]
32. Methods to measure the binding of therapeutic monoclonal antibodies to the human Fc receptor FcγRIII (CD16) using real time kinetic analysis and flow cytometry. Harrison A; Liu Z; Makweche S; Maskell K; Qi H; Hale G J Pharm Biomed Anal; 2012 Apr; 63():23-8. PubMed ID: 22366323 [TBL] [Abstract][Full Text] [Related]
33. Glycoengineering of pertuzumab and its impact on the pharmacokinetic/pharmacodynamic properties. Luo C; Chen S; Xu N; Wang C; Sai WB; Zhao W; Li YC; Hu XJ; Tian H; Gao XD; Yao WB Sci Rep; 2017 Apr; 7():46347. PubMed ID: 28397880 [TBL] [Abstract][Full Text] [Related]
34. Towards the development of a surface plasmon resonance assay to evaluate the glycosylation pattern of monoclonal antibodies using the extracellular domains of CD16a and CD64. Dorion-Thibaudeau J; Raymond C; Lattová E; Perreault H; Durocher Y; De Crescenzo G J Immunol Methods; 2014 Jun; 408():24-34. PubMed ID: 24810583 [TBL] [Abstract][Full Text] [Related]
35. Dynamics of immature mAb glycoform secretion during CHO cell culture: An integrated modelling framework. Jimenez Del Val I; Fan Y; Weilguny D Biotechnol J; 2016 May; 11(5):610-23. PubMed ID: 26743760 [TBL] [Abstract][Full Text] [Related]
36. Production of non-fucosylated antibodies by co-expression of heterologous GDP-6-deoxy-D-lyxo-4-hexulose reductase. von Horsten HH; Ogorek C; Blanchard V; Demmler C; Giese C; Winkler K; Kaup M; Berger M; Jordan I; Sandig V Glycobiology; 2010 Dec; 20(12):1607-18. PubMed ID: 20639190 [TBL] [Abstract][Full Text] [Related]
37. Effect of constant and variable domain glycosylation on pharmacokinetics of therapeutic antibodies in mice. Millward TA; Heitzmann M; Bill K; Längle U; Schumacher P; Forrer K Biologicals; 2008 Jan; 36(1):41-7. PubMed ID: 17890101 [TBL] [Abstract][Full Text] [Related]
38. Insect cells for antibody production: evaluation of an efficient alternative. Palmberger D; Rendić D; Tauber P; Krammer F; Wilson IB; Grabherr R J Biotechnol; 2011 May; 153(3-4):160-6. PubMed ID: 21477625 [TBL] [Abstract][Full Text] [Related]
39. Cell type-specific and site directed N-glycosylation pattern of FcγRIIIa. Zeck A; Pohlentz G; Schlothauer T; Peter-Katalinić J; Regula JT J Proteome Res; 2011 Jul; 10(7):3031-9. PubMed ID: 21561106 [TBL] [Abstract][Full Text] [Related]
40. A single glycosylation site within the receptor-binding domain of the avian sarcoma/leukosis virus glycoprotein is critical for receptor binding. Delos SE; Burdick MJ; White JM Virology; 2002 Mar; 294(2):354-63. PubMed ID: 12009877 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]